BDX
Becton Dickinson
$140.71
▼ 2.3%Updated Today 7:15 PM ET
▲ Up 8.6% over the last 12 months
Market Cap
$39.67B
P/E
35.01x
Forward P/E (est.)
46.58x
ROE
4.5%
Revenue Growth
2.4%
EPS Growth
-24.8%
Profit Margin
5.3%
FCF Yield
9.0%
Debt / Equity
0.76x
ROIC
5.0%
Interest Coverage
4.21x
Current Ratio
0.94x
Dividend Yield
2.9%
Implied Growth (rev. DCF)
2.1%
Rating Score
37/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what BDX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. BDX trades near $140.71, below its 50-day average ($149.23) and 200-day average ($154.09). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 36 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. BDX's is $3.41 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month BDX found buyers near $140.63 (support) and sellers near $153.24 (resistance); its 52-week range is $127.59–$187.35. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.3× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Becton Dickinson (BDX) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $39.67B.
In its latest reported year it generated about $21.84B in revenue and $1.68B in net profit.
Our model rates BDX Weak (37/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
3.4%
Revenue moved from $19.13B in 2021 to $21.84B in 2025, a 3.4% compound annual growth rate. The most recent year was roughly flat (2.4%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
47.0%
Operating Margin
11.8%
Net Margin
7.7%
ROE
4.5%
Becton Dickinson keeps about 5.3% of each sales dollar as net profit, with a 47.0% gross margin and 11.8% operating margin. Return on equity is 4.5% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$15.46B
Net Debt
$14.64B
Net Debt / EBITDA
5.68x
Debt / Equity
0.76x
Leverage: debt-to-equity is 0.8x, and operating profit covers interest about 4.2x, with a current ratio of 0.9x. That is a moderate, manageable debt load for most businesses. It carries roughly $15.46B of total debt against $813.00M of cash.
Operating CF
$3.43B
Free Cash Flow
$2.67B
FCF Margin
12.2%
In the latest year Becton Dickinson produced about $3.43B of operating cash flow and $2.67B of free cash flow after capital spending. That is a free-cash-flow yield of about 9.0% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
35.01x
P/S
1.84x
P/B
2.09x
EV / EBITDA
10.69x
BDX trades at 35.0x trailing earnings (about 46.6x on estimated forward earnings), 1.8x sales, and 2.1x book value. Reverse-engineering today's price implies the market expects roughly 2.1% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How BDX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), BDX ranks #50 of 59 by our overall rating. It trades at a premium versus the sector on earnings (35x P/E vs. 25.4x median) with a lower return on equity (4.5% vs. 14.9%) and slower revenue growth (2.4% vs. 7.9%).
P/E vs sector
35x
median 25.4x
ROE vs sector
4.5%
median 14.9%
Growth vs sector
2.4%
median 7.9%
Sector rank
#50
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$154.37 – $257.28
vs. $140.71 today · expected CAGR 2% – 13%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $22.50B | $23.17B | $23.87B | $24.58B | $25.32B |
| Net income | $1.80B | $1.85B | $1.91B | $1.97B | $2.03B |
| EPS | $6.53 | $6.73 | $6.93 | $7.14 | $7.35 |
| Share price (low) | $137.16 | $141.27 | $145.51 | $149.87 | $154.37 |
| Share price (high) | $228.59 | $235.45 | $242.51 | $249.79 | $257.28 |
| CAGR (low–high) | -3% / 62% | 0% / 29% | 1% / 20% | 2% / 15% | 2% / 13% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for BDX:
- Healthy free-cash-flow yield (~9.0%) funds buybacks and dividends.
- Pays a 2.9% dividend on top of any price gains.
The case against BDX:
- Revenue growth is slow (2.4%), limiting the upside engine.
- Our model's overall read is Weak (37/100).
Valuation risk — at 35.0x earnings, disappointing results could compress the multiple.
Growth risk — sluggish revenue (2.4%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Becton Dickinson is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at 35.0x earnings, which our model scores Weak (37/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.